A Randomised, Double-blind (Sponsor Open), Placebo-controlled, Three Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single (in Both Fed and Fasted States) or Repeat Doses of GSK3358699 in Healthy Male Participants

This FTIH study, intends to identify the doses of GSK3358699, which are well tolerated by the
subjects whilst delivering a robust pharmacodynamic (PD) response. This study will evaluate
the safety, tolerability, pharmacokinetic (PK) and PD profile of single (in both fed and
fasted states) and multiple ascending doses of GSK3358699 in healthy male subjects within a
pre-defined and controlled pharmacodynamic and pharmacokinetic range for each cohort. It also
intends to understand the effect of GSK3358699 on systemic markers of inflammation following
low dose in vivo lipopolysaccharide (LPS) or Granulocyte-Macrophage Colony-Stimulating Factor
(GM-CSF) challenge and local inflammation in cantharidin-induced blisters. The study has been
carefully designed to explore the in vivo biology of the target and the potential for the
study drug to become a transformative medicine for subjects in multiple immuno-inflammatory
disease indications.